热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse CD4 Antibod
产品名称：
Brilliant Violet 421™ anti-mouse CD4 Antibod
产品类别：
抗体
产品编号：
100438
产品应用：
100438
[价格]
规格 价格 库存
500µL ￥ 4488 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
ICC?- Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤0.125 ?g per million cells in 100 ?l volume. For flow cytometric staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation.?Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  13. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  2. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  3. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  4. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  5. Shinohara M 2015. J Immunol. 194:5595. PubMed
  6. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  7. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  8. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  9. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  10. Han Y, et al. 2020. Nat Commun. 11:1776. PubMed
  11. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  12. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  13. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  14. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  15. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  16. Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed
  17. Runge EM, et al. 2020. J Neuroinflammation. 17:121. PubMed
  18. Garg G et al. 2019. Cell reports. 26(7):1854-1868 . PubMed
  19. Alberti D, et al. 2021. Curr Protoc. 1:e311. PubMed
  20. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  21. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  22. Goswami M, et al. 2019. Biomed Opt Express. 10:151. PubMed
  23. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  24. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  25. Li J, et al. 2020. Elife. 9:00. PubMed
  26. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  27. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  28. Marinescu CI, et al. 2021. Stem Cell Res Ther. 12:319. PubMed
  29. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  30. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  31. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  32. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  33. Ercoli G, et al. 2022. Clin Transl Immunology. 11:e1366. PubMed
  34. Hassan AO, et al. 2020. Cell. 183:169. PubMed
  35. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  36. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  37. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  38. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  39. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  40. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  41. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  42. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  43. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  44. Bhatt D, et al. 2021. J Exp Med. 218:. PubMed
  45. Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed
  46. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  47. Silva DA, et al. 2019. Nature. 565:186. PubMed
  48. Bennion BG, et al. 2019. J Virol. 93. PubMed
  49. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  50. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  51. Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed
  52. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  53. Li H, et al. 2022. iScience. 25:104481. PubMed
  54. Alam IS, et al. 2020. Cancer Res. 80:4780. PubMed
  55. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
  56. Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed
  57. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  58. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  59. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID
AB_10900241 (BioLegend Cat. No. 100437) AB_2562557 (BioLegend Cat. No. 100443) AB_11203718 (BioLegend Cat. No. 100438)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线